A Unique Peptide Deformylase Platform to Rationally Design and Challenge Novel Active Compounds

Overview

Journal Sci Rep

Specialty Science

Date 2016 Oct 21

PMID 27762275

Citations 7

Authors

Sonia Fieulaine

Rodolphe Alves de Sousa

Laure Maigre

Karim Hamiche

Mickael Alimi

Jean-Michel Bolla

Abbass Taleb

Alexis Denis

Jean-Marie Pages

Isabelle Artaud

Thierry Meinnel

Carmela Giglione

Affiliations

Soon will be listed here.

Abstract

Peptide deformylase (PDF) is considered an excellent target to develop antibiotics. We have performed an extensive characterization of a new PDF from the pathogen Streptococcus agalactiae, showing properties similar to other known PDFs. S. agalactiae PDF could be used as PDF prototype as it allowed to get complete sets of 3-dimensional, biophysical and kinetic data with virtually any inhibitor compound. Structure-activity relationship analysis with this single reference system allowed us to reveal distinct binding modes for different PDF inhibitors and the key role of a hydrogen bond in potentiating the interaction between ligand and target. We propose this protein as an irreplaceable tool, allowing easy and relevant fine comparisons between series, to design, challenge and validate novel series of inhibitors. As proof-of-concept, we report here the design and synthesis of effective specific bacterial PDF inhibitors of an oxadiazole series with potent antimicrobial activity against a multidrug resistant clinical isolate.

Citing Articles

Inhibitory role of copper and silver nanocomposite on important bacterial and fungal pathogens in rice (Oryza sativa).

Chowdhury A, Kumar R, Mahanty A, Mukherjee K, Kumar S, Tribhuvan K Sci Rep. 2024; 14(1):1779.

PMID: 38245579 PMC: 10799878. DOI: 10.1038/s41598-023-49918-0.

Prediction of Pharmacokinetics of IDP-73152 in Humans Using Physiologically-Based Pharmacokinetics.

Lee M, Jeong Y, Kim M, An K, Chung S Pharmaceutics. 2022; 14(6).

PMID: 35745730 PMC: 9227536. DOI: 10.3390/pharmaceutics14061157.

Metal utilization in genome-reduced bacteria: Do human mycoplasmas rely on iron?.

Peralvarez-Marin A, Baranowski E, Bierge P, Pich O, Lebrette H Comput Struct Biotechnol J. 2021; 19:5752-5761.

PMID: 34765092 PMC: 8566771. DOI: 10.1016/j.csbj.2021.10.022.

Data on molecular docking of naturally occurring flavonoids with biologically important targets.

Moulishankar A, Lakshmanan K Data Brief. 2020; 29:105243.

PMID: 32072001 PMC: 7016233. DOI: 10.1016/j.dib.2020.105243.

Total synthesis of (±)-fumimycin and analogues for biological evaluation as peptide deformylase inhibitors.

Zaghouani M, Bogeholz L, Mercier E, Wintermeyer W, Roche S Tetrahedron. 2019; 75(24):3216-3230.

PMID: 31555018 PMC: 6759494. DOI: 10.1016/j.tet.2019.03.037.

References

Mamelli L, Petit S, Chevalier J, Giglione C, Lieutaud A, Meinnel T . New antibiotic molecules: bypassing the membrane barrier of gram negative bacteria increases the activity of peptide deformylase inhibitors. PLoS One. 2009; 4(7):e6443. PMC: 2713832. DOI: 10.1371/journal.pone.0006443. View

Nguyen K, Hu X, Pei D . Slow-binding inhibition of peptide deformylase by cyclic peptidomimetics as revealed by a new spectrophotometric assay. Bioorg Chem. 2004; 32(3):178-91. DOI: 10.1016/j.bioorg.2004.01.001. View

Giglione C, Pierre M, Meinnel T . Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents. Mol Microbiol. 2000; 36(6):1197-205. DOI: 10.1046/j.1365-2958.2000.01908.x. View

Axten J, Medina J, Blackledge C, Duquenne C, Grant S, Bobko M . Acylprolinamides: a new class of peptide deformylase inhibitors with in vivo antibacterial activity. Bioorg Med Chem Lett. 2012; 22(12):4028-32. DOI: 10.1016/j.bmcl.2012.04.086. View

ODwyer K, Hackel M, Hightower S, Hoban D, Bouchillon S, Qin D . Comparative analysis of the antibacterial activity of a novel peptide deformylase inhibitor, GSK1322322. Antimicrob Agents Chemother. 2013; 57(5):2333-42. PMC: 3632952. DOI: 10.1128/AAC.02566-12. View

Boularot A, Giglione C, Artaud I, Meinnel T . Structure-activity relationship analysis and therapeutic potential of peptide deformylase inhibitors. Curr Opin Investig Drugs. 2004; 5(8):809-22. View

Ragusa S, Blanquet S, Meinnel T . Control of peptide deformylase activity by metal cations. J Mol Biol. 1998; 280(3):515-23. DOI: 10.1006/jmbi.1998.1883. View

Zorzet A, Andersen J, Nilsson A, Moller N, Andersson D . Compensatory mutations in agrC partly restore fitness in vitro to peptide deformylase inhibitor-resistant Staphylococcus aureus. J Antimicrob Chemother. 2012; 67(8):1835-42. DOI: 10.1093/jac/dks168. View

Brown D . Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?. Nat Rev Drug Discov. 2015; 14(12):821-32. DOI: 10.1038/nrd4675. View

10.

Cali P, Naerum L, Mukhija S, Hjelmencrantz A . Isoxazole-3-hydroxamic acid derivatives as peptide deformylase inhibitors and potential antibacterial agents. Bioorg Med Chem Lett. 2004; 14(24):5997-6000. DOI: 10.1016/j.bmcl.2004.09.087. View

11.

Boularot A, Giglione C, Petit S, Duroc Y, Alves de Sousa R, Larue V . Discovery and refinement of a new structural class of potent peptide deformylase inhibitors. J Med Chem. 2007; 50(1):10-20. DOI: 10.1021/jm060910c. View

12.

Moon J, Park J, Kim E . Structure analysis of peptide deformylase from Bacillus cereus. Proteins. 2005; 61(1):217-20. DOI: 10.1002/prot.20526. View

13.

Mazel D, Pochet S, Marliere P . Genetic characterization of polypeptide deformylase, a distinctive enzyme of eubacterial translation. EMBO J. 1994; 13(4):914-23. PMC: 394892. DOI: 10.1002/j.1460-2075.1994.tb06335.x. View

14.

Burchak O, Le Pihive E, Maigre L, Guinchard X, Bouhours P, Jolivalt C . Synthesis and evaluation of 1-(1H-indol-3-yl)ethanamine derivatives as new antibacterial agents. Bioorg Med Chem. 2011; 19(10):3204-15. DOI: 10.1016/j.bmc.2011.03.060. View

15.

Fieulaine S, Desmadril M, Meinnel T, Giglione C . Understanding the highly efficient catalysis of prokaryotic peptide deformylases by shedding light on the determinants specifying the low activity of the human counterpart. Acta Crystallogr D Biol Crystallogr. 2014; 70(Pt 2):242-52. DOI: 10.1107/S1399004713026461. View

16.

Shi W, Duan Y, Qian Y, Li M, Yang L, Hu W . Design, synthesis, and antibacterial activity of 2,5-dihydropyrrole formyl hydroxyamino derivatives as novel peptide deformylase inhibitors. Bioorg Med Chem Lett. 2010; 20(12):3592-5. DOI: 10.1016/j.bmcl.2010.04.123. View

17.

Shah B, Padbury J . Neonatal sepsis: an old problem with new insights. Virulence. 2013; 5(1):170-8. PMC: 3916371. DOI: 10.4161/viru.26906. View

18.

East S, Ayscough A, Toogood-Johnson I, Taylor S, Thomas W . Peptidomimetic inhibitors of bacterial peptide deformylase. Bioorg Med Chem Lett. 2011; 21(13):4032-5. DOI: 10.1016/j.bmcl.2011.04.132. View

19.

Kabsch W . Integration, scaling, space-group assignment and post-refinement. Acta Crystallogr D Biol Crystallogr. 2010; 66(Pt 2):133-44. PMC: 2815666. DOI: 10.1107/S0907444909047374. View

20.

Berendonk T, Manaia C, Merlin C, Fatta-Kassinos D, Cytryn E, Walsh F . Tackling antibiotic resistance: the environmental framework. Nat Rev Microbiol. 2015; 13(5):310-7. DOI: 10.1038/nrmicro3439. View